How effective is pemigatinib?

Pemigatinib (Pemigatinib), as a targeted therapy, has shown significant anti-tumor effects in some patients with cholangiocarcinoma. According to the results of clinical trials, some of the main findings regarding the efficacy of pemetinib includeFGFR2 gene mutations, disease control, and individual differences.

Given the available evidence that targeted FGFR inhibitor therapy may be superior to chemotherapy for FGFR2 fusion cholangiocarcinoma, with a median overall survival of 17.5 months for pemetinib treatment in second-line treatment, ongoing studies to evaluate the efficacy of adjuvant or neoadjuvant FGFR inhibition in stage I-III cholangiocarcinoma are warranted. It should be noted that not all patients with cholangiocarcinoma are suitable for pemetinib, and treatment effects may vary among individual patients. The final treatment plan should be determined by the physician based on the patient's specific circumstances, severity of illness, and other factors.

The original drug of pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 4.5mg*14 tablets may be around 30,000 yuan, which is expensive. The price of the original pemetinib drug, 13.5mg*14 tablets, per box sold overseas may be around RMB 70,000 (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas. For example, the price of a box of 4.5mg*21 tablets produced by a Laos pharmaceutical factory may be around 3,000 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The pharmaceutical ingredients of the generic drugs are basically the same as those of the original drugs at home and abroad.